Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) – Jefferies Group boosted their FY2016 earnings estimates for shares of Dicerna Pharmaceuticals in a research note issued to investors on Thursday. Jefferies Group analyst E. Yang now forecasts that the brokerage will post earnings of ($3.32) per share for the year, up from their prior forecast of ($3.34). Jefferies Group also issued estimates for Dicerna Pharmaceuticals’ Q4 2016 earnings at ($0.94) EPS, FY2017 earnings at ($2.26) EPS, FY2018 earnings at ($1.98) EPS, FY2019 earnings at ($1.74) EPS and FY2020 earnings at ($1.73) EPS.
DRNA has been the subject of several other reports. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a report on Monday. Leerink Swann restated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Thursday, June 30th. Chardan Capital lowered their price target on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a report on Monday, August 8th. Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Sunday, June 26th. Finally, Stifel Nicolaus reduced their price objective on Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, June 30th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Dicerna Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $12.25.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.09.
A number of hedge funds and other institutional investors have recently modified their holdings of DRNA. State Street Corp boosted its position in shares of Dicerna Pharmaceuticals by 20.7% in the first quarter. State Street Corp now owns 209,015 shares of the biopharmaceutical company’s stock valued at $1,123,000 after buying an additional 35,820 shares during the period. Geode Capital Management LLC boosted its stake in Dicerna Pharmaceuticals by 1.4% in the first quarter. Geode Capital Management LLC now owns 101,528 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 1,371 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Dicerna Pharmaceuticals during the first quarter worth about $160,000. Opus Point Partners Management LLC boosted its stake in Dicerna Pharmaceuticals by 8.0% in the first quarter. Opus Point Partners Management LLC now owns 108,000 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 8,000 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Dicerna Pharmaceuticals during the first quarter worth about $343,000. 62.38% of the stock is owned by hedge funds and other institutional investors.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.